Our results showed that Sal B, a promising drug for PAD, improved limb ischemia via M2 macrophage polarization by the SIRT1/PI3K/AKT pathway, thereby exerting an antilimb ischemia effect. Here, SIRT1 is linked to peripheral arterial disease.